Julius Clinical

Julius Clinical operates as a scientifically focused, full-service contract research organization (CRO) with a business model centered on managing complex global clinical trials. The company generates revenue by providing end-to-end clinical trial services to a diverse client base that includes pharmaceutical and biotechnology companies, as well as governments and academic institutions. These services cover all phases of clinical development, from early-stage to post-registration studies, and include project management, study design, patient and investigator recruitment, data management, and biostatistics.

Founded in 2008, the company was established as a spin-off from the renowned Julius Center for Health Sciences and Primary Care at the University Medical Center (UMC) in Utrecht, Netherlands. This academic heritage is a core part of its identity, blending scientific leadership with operational excellence. The founders include Professor Rick Grobbee and Peter Schoevers. Professor Grobbee, a distinguished professor of Clinical Epidemiology with over 1,500 scientific publications, brought deep academic and research credibility, serving as the Chief Scientific Officer. His extensive background in founding the Julius Center and his work in cardiovascular health shaped the company's evidence-based approach. Peter Schoevers provided the commercial and entrepreneurial leadership, drawing from his experience in the pharmaceutical industry to structure the spin-off for international growth.

Julius Clinical differentiates itself by leveraging its strong academic roots and a global network of Key Opinion Leaders (KOLs) and research sites. This approach allows for the execution of trials that are designed to have a significant impact on medical practice. The company specializes in specific therapeutic areas, including Central Nervous System (CNS) disorders like Alzheimer's and Epilepsy, cardio-metabolic diseases, infectious diseases, renal conditions, and rare diseases. A significant milestone occurred in November 2023, when Ampersand Capital Partners, a healthcare-focused private equity firm, made a substantial growth investment to help expand the company's geographic footprint and expertise. This was followed by a merger in May 2025 with Peachtree BioResearch Solutions, a US-based CRO, to enhance its capabilities, particularly in CNS research, and solidify its presence in North America.

Keywords: contract research organization, clinical trials, pharmaceutical services, biotechnology, academic research organization, clinical development, drug development, CNS research, cardiology, infectious diseases, real-world evidence, site management organization, trial management, life sciences, regulatory submission, medical devices, global clinical trials, investigator network, scientific leadership, patient recruitment